PKC Zeta Inhibitor Promotes Lung Injury Repair

Tech DescriptionResearchers at the University of Iowa have developed a potential treatment for patients suffering from ALI, including its most severe form, ARDS. This candidate treatment is the administration of PKC-zeta inhibitors, which block this key early signaling mediator that results in the cessation of proper lung function during periods of severe inflammation. The inhibitor construct that has been studied thus far is the peptide-based inhibitor with the following sequences: Ser-Ile-Tyr-Arg-Arg-Gly-Ala-Arg-Arg-Trp-Arg-Lys-LeuOH. Studies in mouse lung injury models have demonstrated that treatment with this PKC-zeta inhibitor preserve the alveolar epithelial barrier, partially preserve lung compliance, and promote lung repair by promoting lung progenitor cells. Additional studies have shown that this treatment may also be effective for chronic lung disease conditions, such as interstitial lung disease / pulmonary fibrosis. AdvantagesNOVEL TREATMENT PATHWAY AND AGENT. The inhibition of PKC-delta signaling plays a key role in promoting multiple pathways for recovery in patients with acute pulmonary distress. PROMOTES REPAIR OF DAMAGED LUNG TISSUE. Studies have demonstrated that this treatment stimulates the proliferation of tissue types that are damaged and poorly functioning during ALI / ARDS.

USA